Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Progesterone intravenous - BHR Pharma

Next Previous
Drug Profile

Progesterone intravenous - BHR Pharma

Alternative Names: BHR-100

Latest Information Update: 25 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BHR Pharma
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Apoptosis inhibitors; GABA modulators; Glutamate antagonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Lipid peroxidation inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 01 Mar 2014 BHR Pharma complete the global phase III SyNAPSe trial for Brain injuries in USA, Argentina, China, Europe, Israel, Malaysia, Russia, Singapore, Taiwan and Thailand (NCT01143064)
  • 03 Sep 2013 BHR Pharma completes enrolment in the global phase III SyNAPSe trial for Brain injuries (NCT01143064)
  • 13 Feb 2013 Progesterone intravenous - BHR Pharma receives Orphan Drug status for Brain injuries in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top